Gaucher Disease
Also known as: Gaucher's Disease, Glucocerebrosidase Deficiency, GD
Gaucher disease is an inherited metabolic disorder caused by a deficiency of the enzyme glucocerebrosidase. This leads to accumulation of fatty substances in cells and organs, particularly the spleen, liver, and bone marrow.
Gaucher disease happens when the body can't properly clean up certain fats inside cells. These fats pile up and make the liver and spleen grow too big, and can make bones weak. Doctors can give special medicines that help the body clean up these fats.
Signs & Symptoms
- Enlarged spleen (splenomegaly)
- Enlarged liver (hepatomegaly)
- Bone pain and fractures
- Easy bruising
- Fatigue
- Anemia
- Low platelet count
- Delayed growth in children
- Neurological symptoms (Type 2 and 3)
Treatment Options
Imiglucerase (Cerezyme)
HIGHLY EFFECTIVEApproved 1994Velaglucerase alfa (VPRIV)
HIGHLY EFFECTIVEApproved 2010Taliglucerase alfa (Elelyso)
HIGHLY EFFECTIVEApproved 2012Eliglustat (Cerdelga)
HIGHLY EFFECTIVEApproved 2014Miglustat (Zavesca)
MODERATELY EFFECTIVEApproved 2003Bone marrow transplant
CURATIVEDiagnosis
- Enzyme activity assay (glucocerebrosidase)
- Genetic testing for GBA mutations
- Bone marrow biopsy showing Gaucher cells
- Complete blood count
- MRI for bone involvement
- Liver/spleen volume measurement
History
Philippe Gaucher first described the disease in 1882. The enzymatic defect was identified in 1965 by Roscoe Brady at NIH. The development of enzyme replacement therapy by Brady's team in the 1990s revolutionized treatment and served as a model for treating other lysosomal storage disorders.
Recent Breakthroughs
Gene therapy clinical trials advance
AAV-based gene therapy trials show sustained enzyme production and potential for one-time treatment.
New substrate reduction therapies
Next-generation SRT drugs with improved brain penetration show promise for neuronopathic forms.
Parkinson's disease connection clarified
Research reveals molecular mechanisms linking GBA mutations to Parkinson's pathology.